Jefferies Starts Sagent Pharmaceuticals (SGNT) at Buy

Jefferies initiates coverage on Sagent Pharmaceuticals (NASDAQ: SGNT) with a Buy and $31 price target.

The firm states, "Sagent is one of a few standalone generic injectables companies, and given high barriers to entry and limited competition, has compelling scarcity value. With a low-cost business model that should support significant future margin expansion, one of the industry's largest pipelines, and a management team with a track record of success, we initiate coverage at a Buy and $31 PT."

For more ratings news on Sagent Pharmaceuticals click here and for the rating history of Sagent Pharmaceuticals click here.

Shares of Sagent Pharmaceuticals closed at $25.43 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Starts Aehr Test Systems (AEHR) at Buy
• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating